274 related articles for article (PubMed ID: 31330838)
1. Autophagy: New Insights into Mechanisms of Action and Resistance of Treatment in Acute Promyelocytic leukemia.
Moosavi MA; Djavaheri-Mergny M
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330838
[TBL] [Abstract][Full Text] [Related]
2. Targeting HDAC3 to overcome the resistance to ATRA or arsenic in acute promyelocytic leukemia through ubiquitination and degradation of PML-RARα.
Dai B; Wang F; Wang Y; Zhu J; Li Y; Zhang T; Zhao L; Wang L; Gao W; Li J; Zhu H; Li K; Hu J
Cell Death Differ; 2023 May; 30(5):1320-1333. PubMed ID: 36894687
[TBL] [Abstract][Full Text] [Related]
3. The clinically relevant CHK1 inhibitor MK-8776 induces the degradation of the oncogenic protein PML-RARα and overcomes ATRA resistance in acute promyelocytic leukemia cells.
Franza M; Albanesi J; Mancini B; Pennisi R; Leone S; Acconcia F; Bianchi F; di Masi A
Biochem Pharmacol; 2023 Aug; 214():115675. PubMed ID: 37406967
[TBL] [Abstract][Full Text] [Related]
4. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J
Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552
[TBL] [Abstract][Full Text] [Related]
5. Retinoid receptor signaling and autophagy in acute promyelocytic leukemia.
Orfali N; McKenna SL; Cahill MR; Gudas LJ; Mongan NP
Exp Cell Res; 2014 May; 324(1):1-12. PubMed ID: 24694321
[TBL] [Abstract][Full Text] [Related]
6. Autophagy and Ubiquitin-Mediated Proteolytic Degradation of PML/Rarα Fusion Protein in Matrine-Induced Differentiation Sensitivity Recovery of ATRA-Resistant APL (NB4-LR1) Cells: in Vitro and in Vivo Studies.
Wu D; Shao K; Zhou Q; Sun J; Wang Z; Yan F; Liu T; Wu X; Ye B; Huang H; Zhou Y
Cell Physiol Biochem; 2018; 48(6):2286-2301. PubMed ID: 30114705
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic effects of arsenic trioxide on acute promyelocytic leukemia and other types of leukemias.
Yousefnia S
Cell Biol Int; 2021 Jun; 45(6):1148-1157. PubMed ID: 33527587
[TBL] [Abstract][Full Text] [Related]
8. [Acute promyelocytic leukemia: state-of-the-art management].
Asou N
Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
[TBL] [Abstract][Full Text] [Related]
9. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Jing Y
Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
[TBL] [Abstract][Full Text] [Related]
10. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy.
Li T; Ma R; Zhang Y; Mo H; Yang X; Hu S; Wang L; Novakovic VA; Chen H; Kou J; Bi Y; Yu B; Fang S; Wang J; Zhou J; Shi J
Cell Death Dis; 2018 Jan; 9(2):75. PubMed ID: 29362482
[TBL] [Abstract][Full Text] [Related]
12. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
Isakson P; Bjørås M; Bøe SO; Simonsen A
Blood; 2010 Sep; 116(13):2324-31. PubMed ID: 20574048
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms of action and resistance to all-trans retinoic acid (ATRA) and arsenic trioxide (As2O 3) in acute promyelocytic leukemia.
Tomita A; Kiyoi H; Naoe T
Int J Hematol; 2013 Jun; 97(6):717-25. PubMed ID: 23670176
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Leukemia Eradication by Combined Treatment with Retinoic Acid and HIF Inhibition by EZN-2208 (PEG-SN38) in Preclinical Models of PML-RARα and PLZF-RARα-Driven Leukemia.
Coltella N; Valsecchi R; Ponente M; Ponzoni M; Bernardi R
Clin Cancer Res; 2015 Aug; 21(16):3685-94. PubMed ID: 25931453
[TBL] [Abstract][Full Text] [Related]
15. All-trans retinoic acid (ATRA)-induced TFEB expression is required for myeloid differentiation in acute promyelocytic leukemia (APL).
Orfali N; O'Donovan TR; Cahill MR; Benjamin D; Nanus DM; McKenna SL; Gudas LJ; Mongan NP
Eur J Haematol; 2020 Mar; 104(3):236-250. PubMed ID: 31811682
[TBL] [Abstract][Full Text] [Related]
16. LG-362B targets PML-RARα and blocks ATRA resistance of acute promyelocytic leukemia.
Wang X; Lin Q; Lv F; Liu N; Xu Y; Liu M; Chen Y; Yi Z
Leukemia; 2016 Jul; 30(7):1465-74. PubMed ID: 27012866
[TBL] [Abstract][Full Text] [Related]
17. Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia.
Wang QQ; Hua HY; Naranmandura H; Zhu HH
Toxicol Appl Pharmacol; 2020 Dec; 409():115299. PubMed ID: 33091440
[TBL] [Abstract][Full Text] [Related]
18. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk.
Zhu Q; Zhang JW; Zhu HQ; Shen YL; Flexor M; Jia PM; Yu Y; Cai X; Waxman S; Lanotte M; Chen SJ; Chen Z; Tong JH
Blood; 2002 Feb; 99(3):1014-22. PubMed ID: 11807007
[TBL] [Abstract][Full Text] [Related]
19. Role of cardiolipins, mitochondria, and autophagy in the differentiation process activated by all-trans retinoic acid in acute promyelocytic leukemia.
Gianni' M; Goracci L; Schlaefli A; Di Veroli A; Kurosaki M; Guarrera L; Bolis M; Foglia M; Lupi M; Tschan MP; Cruciani G; Terao M; Garattini E
Cell Death Dis; 2022 Jan; 13(1):30. PubMed ID: 35013142
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of the antileukemia activities of retinoid and arsenic.
Nitto T; Sawaki K
J Pharmacol Sci; 2014; 126(3):179-85. PubMed ID: 25319615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]